MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 10th at 3:45 p.m. Pacific time.
The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Contacts:
LHA Investor Relations
Yvonne Briggs, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Bruce Voss, 310-691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.52 |
| Daily Change: | 0.02 1.33 |
| Daily Volume: | 956,571 |
| Market Cap: | US$1.210B |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
